Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Cash & Equivalents (2023 - 2025)

Adagio Medical Holdings (ADGM) has disclosed Cash & Equivalents for 3 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed N/A to $17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $17.1 million for FY2025, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $17.1 million at Adagio Medical Holdings, up from $4.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $28.3 million in Q3 2024, with the low at $1.4 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $12.1 million, with a median of $10.6 million recorded in 2025.
  • Peak annual rise in Cash & Equivalents hit 83.49% in 2025, while the deepest fall reached 83.49% in 2025.
  • Over 3 years, Cash & Equivalents stood at $1.4 million in 2023, then soared by 1946.28% to $28.3 million in 2024, then plummeted by 39.56% to $17.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $17.1 million, $4.7 million, and $8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.